Back to top
more

Celyad (CYAD)

(Delayed Data from NSDQ)

$0.47 USD

0.47
NA

0.00 (0.00%)

Updated May 18, 2023 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYAD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Celyad SA [CYAD]

Reports for Purchase

Showing records 21 - 40 ( 56 total )

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 21

09/30/2020

Company Report

Pages: 6

Celyad Highlights Allogeneic CAR T Platforms at Virtual Research - Development Webinar

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 22

09/29/2020

Daily Note

Pages: 3

Clinical Collaboration With Merck Announced for CYAD-101 and Keytruda

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 23

08/10/2020

Company Report

Pages: 6

2Q20 Results; Plenty of Data Coming in 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 24

07/15/2020

Daily Note

Pages: 3

FDA Clearance of IND Application for CYAD-211 Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 25

06/02/2020

Company Report

Pages: 8

Highlights From ASCO 2020; alloSHRINK Data Encouraging

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 26

05/07/2020

Company Report

Pages: 8

1Q20 Results; Trials Remain on Track From Last Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 27

03/25/2020

Company Report

Pages: 8

FY2019 Results; Slight Development Delays Due to COVID-19; Lowering PT to $37

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 28

12/11/2019

Company Report

Pages: 8

Highlights From Investor Meeting and Presentations at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 29

11/22/2019

Company Report

Pages: 8

Celyad Receives €8.5M in Grants and Non-Dilutive Funding

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 30

11/19/2019

Company Report

Pages: 8

3Q19 Highlights; Data Updates Coming at ASH and 1H20 for Innovative CAR-T Therapies

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 31

11/11/2019

Company Report

Pages: 5

Solid Tumor Update at SITC; Adjusting Price Target for Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 32

09/04/2019

Daily Note

Pages: 3

First Patient Dosed With CYAD-01 Manufactured With OptimAb

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 33

08/26/2019

Company Report

Pages: 6

2H19 Results; Additional DEPLETHINK and alloSHRINK Data Expected by YE19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 34

07/05/2019

Company Report

Pages: 6

CYAD-01 and CYAD-101 Updates Presented at ESMO WCGI; Lowering PT as We Are Adjusting Our Launch Timing Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 35

07/02/2019

Company Report

Pages: 6

AML and MDS Updates Regarding Manufacturing and Expected Timing of Data; Conference Call at 8am ET

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 36

06/17/2019

Daily Note

Pages: 4

Encouraging THINK and DEPLETHINK Data at EHA, More Data Expected by YE19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 37

05/17/2019

Company Report

Pages: 6

Abstracts From European Hematology Association Include DEPLETHINK Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 38

03/29/2019

Company Report

Pages: 6

2018 Results; CFO Moves to CEO Role

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 39

03/19/2019

Company Report

Pages: 8

Celyad R-D Day Highlights: CYAD-01 and CYAD-101 Progress and Next Generation Products; Raising Price Target to $52

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Celyad SA

Industry: Medical - Biomedical and Genetics

Record: 40

01/10/2019

Company Report

Pages: 8

Celyad Defines 2019 Priorities With CYAD-01 Acceleration in r/r AML and MDS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party